Evolink expert team participated in the Baikal Forum. Poultry farming: exchange of experience". It is an annual event for owners and managers of poultry farms, genetic companies, manufacturers of feed additives, veterinary medicines and poultry equipment from India, China, Turkey, Kazakhstan, Belarus and Russia; it has been held for more than 28 years.
Alexey Laishevtsev, Director of Development and Co-founder of Evolink, Head of the Laboratory of RES RAS, Candidate of Biological Sciences, and Tatyana Shcherbakova, Executive Director of Evolink, delivered a report at the conference. They told the forum participants about Evolink's product line, development, achievements and plans.
According to the National Veterinary Association, the volume of the entire veterinary products market by the end of 2023 amounted to 97.7 billion rubles. The share of the main domestic producers, including VNIIZH, Stavropol Biofactory, Armavir Biofactory, Avivak, accounts for only 40% of the existing demand in the veterinary drugs market. Evolink is one of the promising domestic manufacturers, the company develops vaccines and other veterinary drugs based on its own laboratory and introduces them into production. When creating vaccines, a new technology based on current strains is used.
Alexey Laishevtsev, Director of Development and Co-founder of Evolink, Head of the Laboratory of RES RAS, Candidate of Biological Sciences, and Tatyana Shcherbakova, Executive Director of Evolink, delivered a report at the conference. They told the forum participants about Evolink's product line, development, achievements and plans.
According to the National Veterinary Association, the volume of the entire veterinary products market by the end of 2023 amounted to 97.7 billion rubles. The share of the main domestic producers, including VNIIZH, Stavropol Biofactory, Armavir Biofactory, Avivak, accounts for only 40% of the existing demand in the veterinary drugs market. Evolink is one of the promising domestic manufacturers, the company develops vaccines and other veterinary drugs based on its own laboratory and introduces them into production. When creating vaccines, a new technology based on current strains is used.